Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities

Microorganisms. 2022 Oct 17;10(10):2048. doi: 10.3390/microorganisms10102048.

Abstract

The gut microbiota has emerged as a key modulator of cancer treatment responses in terms of both efficacy and toxicity. This effect is clearly mediated by processes impacting the activation and modulation of immune responses. More recently, the ability to regulate chemotherapeutic drug metabolism has also emerged as a key driver of response, although the direct mechanisms have yet to be fully elucidated. Through fermentation, the gut microbiota can produce several types of metabolites, including short-chain fatty acids (SCFAs). SCFAs play an important role in maintaining epithelial barrier functions and intestinal homeostasis, with recent work suggesting that SCFAs can modulate response to cancer treatments and influence both anti-tumor immune response and inflammatory-related side effects. In this review, we will discuss the importance of SCFAs and their implications for cancer treatment response and toxicities.

Keywords: cancer; chemotherapy; immunotherapy; microbiota; radiotherapy; short-chain fatty acids; supportive care; treatment response.

Publication types

  • Review

Grants and funding

HR Wardill is supported by the Hospital Research Foundation Group. CB Subramaniam received an Australian Government Research Training Program Stipend.